The fact that there is no evidence confirming the brain disease attribution is, at this point, irrelevant. What we are dealing with here is fashion, politics and money. This level of intellectual /scientific dishonesty is just too egregious for me to continue to support by my membership. from Loren Mosher’s letter of resignation to the […]
One thing I’ve noticed in life is that the most desirable trait in other people, almost a magnet, is humility – people who are right-sized about what they know and what they are. And yet it might well be the most impossible thing of all to achieve in one’s own life. This morning, we heard […]
It’s been quite a couple of weeks. The newshound I live with has had the Kennedy retrospectives and now the Mandela retrospectives running in the background almost constantly. It’s interesting to see so much footage of events that I was around for, and remember what those times felt like long before history had them organized. […]
My practice as a long term psychotherapist in a cosmopolitan city hardly prepared me for a rural charity clinic in Appalachia. It wasn’t an unfamiliar place, but it was an alien practice environment. More than that, I’d been a Rip Van Winkle to the Age of Psychopharmacology, and it was a shock to meet patients […]
There’s a fascinating interview in the BMJ worth anyone’s time to read: FDA official: “clinical trial system is broken” by Deborah Cohen, investigations editor British Medical Journal. 2013 347:f6980. [full text on-line] First, a word about the FDA as a reminder. The FDA was established to insure the safety of foods and drugs in 1906 […]
Varenicline, smoking cessation, and neuropsychiatric adverse events. by Gibbons RD, and Mann JJ. American Journal of Psychiatry. 2013 170[12]:1460-1467. OBJECTIVE In 2009, the U.S. Food and Drug Administration issued a black box warning for varenicline regarding neuropsychiatric events. The authors used data from randomized controlled trials and from a large Department of Defense [DOD] observational […]
Why did it take 19 months to retrieve clinical trial data from a non-profit organisation? by Asbjørn Hróbjartsson, The Nordic Cochrane Centre, Copenhagen, Denmark British Medical Journal. 2013 347:f6927. [full text on-line] Missing data in clinical trials is a major problem. One would expect the situation to be better for trials funded by large non-profit […]
KMSP-TV
from davidhealy.org From: Rasi Guido <Guido.Rasi@ema.europa.eu> Date: 5 December 2013 11:10 Subject: Update on EMA appeal of EU Court interim measures decision in AbbVie and InterMune court cases To: Dear colleagues and friends, I have written a number of times over the past months to keep you informed of developments in the AbbVie and Intermune cases. There […]
U faculty calls for review of controversial drug study Star Tribune by JEREMY OLSON December 5, 2013 Nearly a decade after Dan Markingson died by suicide while participating in a U of M drug trial for schizophrenics, the U’s Faculty Senate raised his death as a reason to re-examine their institution’s handling of vulnerable research […]